# Nuclide record sclc (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/sclc/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "sclc" ;
  schema:name "Small-cell lung cancer"@en ;
  schema:description "A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."@en ;
  schema:url <https://nuclide.cc/indications/sclc/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Small-cell_carcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q738170> ;
  schema:citation <https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq>, <https://www.iaslc.org/iaslc-news/press-release/tarlatamab-anti-pd-l1-first-line-maintenance-after-chemo-immunotherapy-es> ;
  nuclide:tag "lung" ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/dll3/>, <https://nuclide.cc/targets/b7h3/>, <https://nuclide.cc/targets/sstr2/>, <https://nuclide.cc/targets/parp/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/>, <https://nuclide.cc/companies/merck/>, <https://nuclide.cc/companies/bms/> ;
  nuclide:institutions <https://nuclide.cc/institutions/mskcc/>, <https://nuclide.cc/institutions/md-anderson/>, <https://nuclide.cc/institutions/dana-farber/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:standardOfCare <https://nuclide.cc/drugs/durvalumab/>, <https://nuclide.cc/drugs/durvalumab/>, <https://nuclide.cc/technologies/ct/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/drugs/durvalumab/>, <https://nuclide.cc/drugs/durvalumab/>, <https://nuclide.cc/drugs/ryz101/> .